Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.59
AGEN's Cash-to-Debt is ranked lower than
85% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. AGEN: 0.59 )
Ranked among companies with meaningful Cash-to-Debt only.
AGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24  Med: 2.29 Max: 106.58
Current: 0.59
0.24
106.58
Equity-to-Asset -0.25
AGEN's Equity-to-Asset is ranked lower than
94% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. AGEN: -0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
AGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.33  Med: 0.08 Max: 0.92
Current: -0.25
-1.33
0.92
Piotroski F-Score: 3
Altman Z-Score: -8.68
Beneish M-Score: -3.83
WACC vs ROIC
23.10%
-778.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -476.13
AGEN's Operating Margin % is ranked lower than
69% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. AGEN: -476.13 )
Ranked among companies with meaningful Operating Margin % only.
AGEN' s Operating Margin % Range Over the Past 10 Years
Min: -1427.54  Med: -634.16 Max: -42.23
Current: -476.13
-1427.54
-42.23
Net Margin % -562.60
AGEN's Net Margin % is ranked lower than
72% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. AGEN: -562.60 )
Ranked among companies with meaningful Net Margin % only.
AGEN' s Net Margin % Range Over the Past 10 Years
Min: -1161.86  Med: -657.35 Max: -70.95
Current: -562.6
-1161.86
-70.95
ROE % -884.64
AGEN's ROE % is ranked lower than
98% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. AGEN: -884.64 )
Ranked among companies with meaningful ROE % only.
AGEN' s ROE % Range Over the Past 10 Years
Min: -884.64  Med: -460.59 Max: -187.92
Current: -884.64
-884.64
-187.92
ROA % -64.03
AGEN's ROA % is ranked lower than
73% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AGEN: -64.03 )
Ranked among companies with meaningful ROA % only.
AGEN' s ROA % Range Over the Past 10 Years
Min: -94.08  Med: -61.71 Max: -46.32
Current: -64.03
-94.08
-46.32
ROC (Joel Greenblatt) % -541.36
AGEN's ROC (Joel Greenblatt) % is ranked lower than
51% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. AGEN: -541.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -986.59  Med: -329.33 Max: -196.65
Current: -541.36
-986.59
-196.65
3-Year Revenue Growth Rate 36.40
AGEN's 3-Year Revenue Growth Rate is ranked higher than
81% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. AGEN: 36.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.9  Med: -5.4 Max: 96.1
Current: 36.4
-53.9
96.1
3-Year EBITDA Growth Rate 12.80
AGEN's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. AGEN: 12.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.9  Med: -14.2 Max: 68.1
Current: 12.8
-50.9
68.1
3-Year EPS without NRI Growth Rate 9.20
AGEN's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. AGEN: 9.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: -15.8 Max: 30.1
Current: 9.2
-39.7
30.1
GuruFocus has detected 5 Warning Signs with Agenus Inc $AGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AGEN's 10-Y Financials

Financials (Next Earnings Date: 2017-06-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AGEN Guru Trades in Q1 2016

Robert Bruce 233,515 sh (unchged)
Ken Fisher 91,632 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 1,140,315 sh (-5.30%)
Steven Cohen 1,536,948 sh (-60.14%)
» More
Q2 2016

AGEN Guru Trades in Q2 2016

Ken Fisher 93,132 sh (+1.64%)
Robert Bruce 233,515 sh (unchged)
Steven Cohen Sold Out
Jim Simons 517,017 sh (-54.66%)
» More
Q3 2016

AGEN Guru Trades in Q3 2016

Jim Simons Sold Out
Ken Fisher 62,549 sh (-32.84%)
Robert Bruce 155,677 sh (-33.33%)
» More
Q4 2016

AGEN Guru Trades in Q4 2016

Steven Cohen 31,400 sh (New)
Robert Bruce 155,677 sh (unchged)
Ken Fisher 62,549 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:AVDL, NAS:MRUS, NAS:PRTK, NAS:RXDX, NAS:TLGT, NAS:CNCE, NAS:OTIC, NAS:MACK, NAS:IDRA, NAS:BOLD, NAS:BSTC, NAS:ARNA, NAS:SYRS, NAS:CCXI, NAS:AKBA, AMEX:BTX, NAS:CLDX, NAS:OMED, NAS:NSTG, NAS:CRIS » details
Traded in other countries:AJ81.Germany,
Agenus Inc along with its subsidiaries is a biopharmaceutical company. The Company is engaged in developing and commercializing technologies to treat cancers and degenerative disorders.

Agenus is an American biotechnology company. Its main target are immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs.

Ratios

vs
industry
vs
history
PS Ratio 15.46
AGEN's PS Ratio is ranked lower than
54% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. AGEN: 15.46 )
Ranked among companies with meaningful PS Ratio only.
AGEN' s PS Ratio Range Over the Past 10 Years
Min: 4.59  Med: 25.16 Max: 221.6
Current: 15.46
4.59
221.6
Current Ratio 2.24
AGEN's Current Ratio is ranked lower than
70% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. AGEN: 2.24 )
Ranked among companies with meaningful Current Ratio only.
AGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.24  Med: 4.64 Max: 21.68
Current: 2.24
2.24
21.68
Quick Ratio 2.23
AGEN's Quick Ratio is ranked lower than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AGEN: 2.23 )
Ranked among companies with meaningful Quick Ratio only.
AGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.23  Med: 4.61 Max: 21.68
Current: 2.23
2.23
21.68
Days Sales Outstanding 183.56
AGEN's Days Sales Outstanding is ranked lower than
89% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. AGEN: 183.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.12  Med: 20.97 Max: 183.56
Current: 183.56
0.12
183.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.80
AGEN's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. AGEN: -33.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -22.2 Max: -1.5
Current: -33.8
-52
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.61
AGEN's Price-to-Median-PS-Value is ranked higher than
79% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. AGEN: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.14 Max: 141.75
Current: 0.61
0.23
141.75
Earnings Yield (Greenblatt) % -23.94
AGEN's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. AGEN: -23.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -61.08  Med: 0 Max: 0
Current: -23.94
-61.08
0

More Statistics

Revenue (TTM) (Mil) $22.57
EPS (TTM) $ -1.47
Beta3.16
Short Percentage of Float17.00%
52-Week Range $2.97 - 7.49
Shares Outstanding (Mil)98.33

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19 19 10
EPS ($) -1.23 -1.20 -1.23
EPS without NRI ($) -1.23 -1.20 -1.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
Insiders Roundup: Facebook, Twitter, Kellogg Feb 17 2017 
Weekly CEO Buys Highlights Mar 14 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 

More From Other Websites
ETFs with exposure to Agenus, Inc. : March 27, 2017 Mar 27 2017
Agenus to Participate at Two Upcoming Immuno-Oncology Conferences Mar 24 2017
AGENUS INC Financials Mar 23 2017
Agenus, Inc. :AGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Agenus, Inc. :AGEN-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Mar 21 2017
Agenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : March 20, 2017 Mar 20 2017
AGENUS INC Files SEC form 10-K, Annual Report Mar 16 2017
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4 Mar 10 2017
Agenus (AGEN) Reports Narrower-than-Expected Q4 Loss Mar 09 2017
These 5 Stocks Under $10 Could Ignite Soon Mar 09 2017
Agenus reports 4Q loss Mar 09 2017
Agenus reports 4Q loss Mar 09 2017
AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 09 2017
Agenus Reports Fourth Quarter and Full Year 2016 Results Mar 09 2017
Q4 2016 Agenus Inc Earnings Release - Before Market Open Mar 09 2017
Agenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : March 7, 2017 Mar 07 2017
Four Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research... Mar 07 2017
Agenus to Report Fourth Quarter and Year End 2016 Financial Results on March 9, 2017; Conference... Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)